Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.2452W HIGH $12.46
Volume
143.49 K
Value Traded
418.82 K
Short % Float
6.43%
-1.83%Week
-21.84%1 Month
-31.78%3 Month
-41.56%6 Month
-78.54%5 Year
-89.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
153.75 M
EPS (TTM)
-8.26
P/E Ratio
-
Ent. Value
78.48 M
Total Shares
47.75 M
Float Shares
37.68 M
Insiders
21.08%
Institutions
75.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NERV Catalyst Timeline
Dated clinical, regulatory and corporate events for Minerva Neurosciences, Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Minerva Neurosciences, Inc
444Total events
5Upcoming
100Tier-1 (high impact)
2014 to 2030Coverage
Upcoming catalysts 2
Event history 50
●Trial InitiationRoluperidoneFiledTrial
Confirmatory Phase 3 trial (C19) ongoing
negative symptoms of schizophreniasource ↗
◆Oral PresentationPresentation
Minerva Neurosciences to participate in 2026 Jefferies Global Healthcare Conference fireside chat
▲Trial InitiationRoluperidoneFiledTrial
Phase 3 confirmatory trial MIN-101C19 initiated
negative symptoms of schizophreniasource ↗
▲Trial InitiationRoluperidoneFiledTrial
Confirmatory Phase 3 trial of roluperidone initiated
negative symptoms of schizophreniasource ↗
◆Management ChangeCorporate
Jim O'Connor appointed as Chief Business Officer and General Counsel, effective April 21, 2026
◆Trial InitiationRoluperidoneFiledTrial
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia planned for Q2 2026
negative symptoms of schizophreniasource ↗
▲First Patient DosedRoluperidoneFiledTrial
First patient screened in global Phase 3 confirmatory trial of roluperidone
negative symptoms of schizophreniasource ↗
▲Oral PresentationRoluperidoneFiledPresentation
Presentation of open-label safety trial data for roluperidone co-administered with olanzapine at SIRS 2026
negative symptoms of schizophreniasource ↗
◆Enrollment UpdateRoluperidoneFiledTrial
Confirmatory Phase 3 trial now enrolling
negative symptoms of schizophreniasource ↗
◆Oral PresentationPresentation
Minerva Neurosciences presentation at Stifel 2026 Virtual CNS Forum
◆Oral PresentationPresentation
Minerva Neurosciences presentation at Citizens Life Sciences Conference
◆Oral PresentationRoluperidoneFiledPresentation
Virtual KOL event to discuss roluperidone for negative symptoms of schizophrenia
negative symptoms of schizophreniasource ↗
▲Oral PresentationRoluperidoneFiledPresentation
Open label trial data presented at SIRS 2026
negative symptoms of schizophreniasource ↗
▼Equity OfferingCorporate
Private placement of up to $200 million, with initial $80 million upfront
◆FDA Feedback ReceivedRoluperidoneFiledFDA Meeting
FDA confirmed requirement for confirmatory study of roluperidone
negative symptoms of schizophreniasource ↗
▲FDA Feedback ReceivedRoluperidoneFiledFDA Meeting
FDA alignment on confirmatory Phase 3 trial design for roluperidone
negative symptoms of schizophreniasource ↗
▼Complete Response LetterRoluperidoneFiledFDA Decision
FDA issued Complete Response Letter for roluperidone NDA
negative symptoms of schizophreniasource ↗
◆PDUFA DateRoluperidoneFiledRegulatory Filing
PDUFA goal date of February 26, 2024 for roluperidone
negative symptoms in schizophreniasource ↗
▼Complete Response LetterRoluperidoneFiledFDA Decision
FDA issued Complete Response Letter for roluperidone NDA
negative symptoms in patients with schizophreniasource ↗
▼Complete Response LetterRoluperidoneFiledFDA Decision
FDA issued Complete Response Letter for roluperidone NDA
negative symptoms in patients with schizophreniasource ↗
▲Trial CompletionRoluperidoneFiledTrial
Completed Phase 1b trial of roluperidone co-administered with olanzapine
negative symptoms of schizophreniasource ↗
▼Equity OfferingCorporate
Completed $20 million private investment in public equity financing from Boehringer Ingelheim and Federated Hermes Kaufmann Funds
▲FDA Filing AcceptedRoluperidoneFiledRegulatory Filing
FDA confirms acceptance of NDA filing for roluperidone
negative symptoms in schizophreniasource ↗
●Standard Review AssignedRoluperidoneFiledRegulatory Filing
Standard review classification assigned to roluperidone NDA
negative symptoms in schizophreniasource ↗
▲FDA Filing AcceptedRoluperidoneFiledRegulatory Filing
FDA filed NDA for roluperidone
negative symptoms in schizophreniasource ↗
▲Formal Dispute ResolutionRoluperidoneFiledFDA Meeting
FDA granted appeal of refuse-to-file decision
negative symptoms in schizophreniasource ↗
◆FDA Feedback ReceivedRoluperidoneFiledFDA Meeting
Met with FDA to address Refuse to File issues
negative symptoms of schizophreniasource ↗
◆Formal Dispute ResolutionRoluperidoneFiledFDA Meeting
Submitted Formal Dispute Resolution Request (FDRR) to FDA
negative symptoms of schizophreniasource ↗
●Type A MeetingRoluperidoneFiledFDA Meeting
Type A meeting requested with FDA
negative symptoms in schizophreniasource ↗
●Type A MeetingRoluperidoneFiledFDA Meeting
Type A meeting with FDA to discuss RTF
negative symptoms of schizophreniasource ↗
Past FDA Catalysts and PDUFA Decisions
How NERV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-02-27 | Roluperidone (MIN-101) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$7M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 72%
Micro Cap(rank 474 of 658)
Percentile Rank
Minerva Neurosciences, Inc faces pipeline headwinds (29/100), with $90M risk-adjusted pipeline value, led by MIN-101 in Healthy Subjects (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MIN-101 Small moleculeCompletedNCT03038646 | Healthy Subjects | Phase 1 | COMPLETED | 37 | Apr 20, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every NERV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| roluperidone | negative symptoms of schizophrenia | 2026-03-26 | no significant safety concerns or adverse effectsRead More | Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| O'Connor James JosephOfficer (Chief Business Officer and GC) | Grant/Award | 350,800 350,800 held | $0.00 | 04/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NERV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Vivo Capital, LLC | 2.2 % | 23.99 M | 4.32 M |
NERV Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NERV ranks across every disease it competes in
Competitive Position is a premium feature
See how NERV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNERV News
NERV▼ -5.7%on this news
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
Minerva Neurosciences, Inc. will participate in two investor conferences in September 2026. The Wells Fargo Healthcare Conference will take place on September 8, followed by the Cantor Global Healthcare Conference on September 9. Management will engage in 1x1 meetings and a fireside chat, highlighting their focus on CNS disorders.
Read more →NERVMinerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Minerva Neurosciences reported its second quarter 2026 financial results, highlighting the ongoing confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia. The trial aims to enroll 380 patients globally, with topline efficacy data expected in the second half of 2027. Despite a significant net loss, the company remains focused on its unique position in addressing an unmet need in schizophrenia treatment.
Read more →NERVMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Minerva Neurosciences has established a Scientific Advisory Board to guide the Phase 3 trial of roluperidone, aimed at treating negative symptoms of schizophrenia. The board comprises experts in psychiatry and neuroscience, enhancing the company's research and development strategy. The trial is crucial as it targets an area with no approved therapies in the U.S.
Read more →NERV▼ -9%on this news
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva Neurosciences, Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference scheduled for June 2-4, 2026, in New York. CEO Remy Luthringer will represent the company, which specializes in therapies for central nervous system disorders. Attendees can arrange meetings with the Minerva team through Jefferies representatives. A replay of the presentation will be accessible for 90 days post-event.
Read more →NERVMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Minerva Neurosciences reported its first quarter 2026 financial results, announcing the initiation of a confirmatory Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia. The trial aims to confirm the drug's effectiveness and will enroll approximately 380 adults. The company noted a significant financial loss for the quarter, attributed to rising R&D and administrative expenses. Despite these financial challenges, the company remains optimistic about the unique potential of roluperidone in addressing unmet medical needs in mental health.
Read more →NERVMinerva Announces Leadership Transition
Minerva Neurosciences has appointed Jim O'Connor as Chief Business Officer, effective April 21, 2026, following the departure of President Geoff Race. Race will continue as a consultant, having significantly contributed to the company's development since 2010. O'Connor aims to advance Minerva's strategy and lead the upcoming Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia.
Read more →NERV▼ -5.7%on this newsshared move
Minerva Announces Leadership Transition Jim O'Connor joins as Chief Business Officer and General Counsel
Minerva Neurosciences has announced a leadership transition, appointing Jim O'Connor as Chief Business Officer and General Counsel. This change follows the departure of Geoff Race, the company's former President, who will continue to contribute as a consultant. O'Connor's extensive background in legal and business leadership positions him to advance Minerva's initiatives, particularly in the development of roluperidone for treating negative symptoms of schizophrenia. The company is optimistic that this transition will enhance their strategic direction and assist in upcoming clinical trials.
Read more →NERV▼ -7.1%on this newsshared move
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences has initiated a global Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia. This trial follows positive results from earlier studies and aims to enroll approximately 380 patients. Efficacy data is expected in the second half of 2027, addressing a significant unmet medical need in this patient population.
Read more →NERVMinerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Minerva Neurosciences presented positive data from its open-label safety trial of roluperidone co-administered with olanzapine at the SIRS 2026 conference. The trial showed no significant safety concerns or adverse effects, supporting the ongoing Phase 3 trial, which is currently enrolling participants. Topline results are anticipated in late 2027.
Read more →NERV▲ +5.3%on this news
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Minerva Neurosciences, Inc. will participate in The Stifel 2026 Virtual CNS Forum on March 17-18, 2026. CEO Remy Luthringer will represent the company during the event. Interested parties can arrange virtual meetings through their Stifel representatives. A replay of the presentation will be available for ninety days post-event.
Read more →NERV▼ -8.1%on this newsshared move
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Minerva Neurosciences announced its financial results for the fourth quarter and fiscal year 2025, including a planned initiation of a confirmatory Phase 3 trial for roluperidone targeting negative symptoms of schizophrenia in Q2 2026. The company experienced a considerable net loss for Q4 2025, amounting to $283.7 million, which has raised concerns regarding its financial stability. Minerva also reported an increase in total liabilities, which amounted to $233.8 million for the year. Despite these challenges, the recent $80 million financing bolsters its capacity to advance clinical development.
Read more →NERVMinerva Neurosciences to Participate in The Citizens Life Sciences Conference
Minerva Neurosciences, Inc. will participate in The Citizens Life Sciences Conference on March 10-11, 2026, in Miami, FL. CEO Remy Luthringer will represent the company, which is focused on CNS disorder therapies. A replay of the presentation will be accessible for 90 days post-event. The company is also initiating a Phase 3 trial for its drug roluperidone.
Read more →NERV▲ +6.9%on this news
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Minerva Neurosciences is hosting a virtual KOL event on February 3, 2026, to discuss the negative symptoms of schizophrenia and the upcoming Phase 3 trial of roluperidone. Experts Gregory Strauss and Brian Kirkpatrick will address the challenges in assessing these symptoms and the potential of roluperidone as a treatment. This event highlights the ongoing unmet medical need for effective therapies targeting negative symptoms in schizophrenia.
Read more →NERVMinerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Minerva Neurosciences has appointed Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to its Board of Directors. Dr. Kaul is set to aid in the clinical development of roluperidone, particularly focusing on a Phase 3 trial for negative symptoms in schizophrenia. This appointment comes after the company's successful $200 million private placement aimed at funding this trial and related activities. The move is seen as a means to strengthen the company's clinical operations and address a significant unmet need in schizophrenia treatment.
Read more →NERVMinerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences reported its third quarter 2025 financial results, highlighting an $80 million financing to support its Phase 3 trial for roluperidone in treating schizophrenia. The company anticipates sufficient funds for the trial and NDA resubmission, despite a net loss of $2.7 million for the quarter. Cash reserves have decreased significantly compared to the previous year.
Read more →NERV▲ +141%on this news
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva Neurosciences has announced a financing deal worth up to $200 million to support the Phase 3 confirmatory trial of roluperidone, aimed at treating negative symptoms in schizophrenia patients. The funding includes an initial $80 million and potential additional funds based on milestone achievements. The company is also preparing for a resubmission of its New Drug Application (NDA) and a potential U.S. commercial launch, pending approval.
Read more →NERV▲ +141%on this newsshared move
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with
Minerva Neurosciences has announced a financing agreement for up to $200 million to support the development of roluperidone, targeting negative symptoms in schizophrenia patients. The funding will facilitate a Phase 3 confirmatory trial and the resubmission of its New Drug Application (NDA). The agreement includes an upfront payment, with additional funds contingent upon milestone achievements. Minerva also plans to enhance its board with experienced directors to bolster clinical operations. This financial backing aligns with recent FDA guidance on trial design, positioning Minerva towards a potential commercial launch.
Read more →NERVMinerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Minerva Neurosciences has announced an update regarding the FDA's requirement for a confirmatory study for roluperidone, aimed at treating negative symptoms of schizophrenia, following a previous Complete Response Letter. The company will conduct this trial, which may impact their previously planned New Drug Application resubmission. Financial results for Q2 2025 showed a reduced net loss compared to the same period last year, driven by lower research and development costs. However, Minerva is exploring strategic alternatives to enhance shareholder value, reflecting concerns related to its current cash position.
Read more →NERVMinerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences, Inc. has reported its financial results for the first quarter of 2025, highlighting positive developments such as regaining compliance with Nasdaq Listing Rules. The company experienced a notable reduction in net loss, reaching $3.8 million compared to $8.6 million in the same quarter last year. However, it continues to address regulatory feedback from the FDA regarding its New Drug Application for roluperidone while its cash position has slightly declined.
Read more →About Minerva Neurosciences, Inc
Headquarters1500 DISTRICT AVENUE, BURLINGTON, MA, 01803
BIOPHARMAWATCH ELITE PLUS
Trade the next NERV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime